|
Product Information |
|
Product name |
Molnupiravir / EIDD-2801 / MK448 |
|
CAS No. |
2349386-89-4 |
|
Molecular Formula |
C13H19N3O7 |
|
Molecular Weight |
329.31 |
|
Quality Standard |
98% up by HPLC |
|
Appearance |
White powder |
|
COA of Molnupiravir |
|
ITEMS |
SPECIFICATION |
RESULT |
|
Appearance |
White to off-white powder |
White powder |
|
Solubility |
Sparingly soluble in methanol ,practically insoluble in water |
Complies |
|
Identity |
IR Spectrum of the test is concordant with the IR spectrum of the standard, obtained in the samemanner. |
Complies |
|
Related Substance |
Any single impurity not more than 0.1% |
0.04% |
|
Total impurities are not more than1.0% |
0.1% |
|
|
Limit of residual solvents |
2-propanol ≤ 5000ppm |
75 ppm |
|
Ethanol ≤ 5000ppm |
162 ppm |
|
|
Ethyl acetate ≤ 5000ppm |
Not detected |
|
|
Cyclohexane ≤ 3880ppm |
1 ppm |
|
|
Loss on drying |
≤ 0.5% |
0.12% |
|
Residue on ignition |
≤ 0.1% |
0.03% |
|
Heavy metals |
≤ 0.02% |
Complies |
|
Assay |
98.0～102.0% |
99.5% |
|
Conclusion |
Complies with the specification |
|
|
Usage |
Function of Molnupiravir
Molnupiravir / EIDD-2801 is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. EIDD-2801 has broad-spectrum antiviral activity against influenza virus and multiple coronaviruses (e.g., SARS-ChemicalbookCoV-2, MERS-CoV, SARS-CoV). EIDD-2801 has the potential to treat the novel coronavirus COVID-19 as well as seasonal and pandemic influenza.
sinoway se estableció en 1987 y se especializa en investigación, desarrollo, fabricación personalizada y comercialización de productos farmacéuticos apis, intermedios, salud y salud; Complementos alimenticios, materias primas cosméticas, extractos de hierbas, archivos PDF y servicio personalizado en todo el mundo.
IPv6 red compatible
español
English
中文
français
Deutsch
русский
português
العربية
日本語
한국의
Türkçe
